OPXA Insider Trading Activity and SEC Form 4 Filings
OPXA insider trading summary
No open-market insider purchases or sales of Opexa Therapeutics, Inc. (OPXA) have been reported on SEC Form 4 in the past 12 months.
Latest OPXA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 18, 2016 | Timothy C Barabe | Director | Sell | $4K (7,809 @ $0.55) |
| Nov 18, 2016 | Timothy C Barabe | Director | Sell | $4K (7,105 @ $0.55) |
| Sep 17, 2014 | Timothy C Barabe | Director | Buy | $12K (10,000 @ $1.15) |
| Sep 16, 2014 | Neil K Warma | President & CEO | Buy | $11K (10,000 @ $1.11) |
| Dec 18, 2013 | Scott B Seaman | Director | Buy | $51K (30,000 @ $1.70) |
| Dec 18, 2013 | Karthik Radhakrishnan | Chief Financial Officer | Buy | $14K (8,000 @ $1.70) |
| Aug 8, 2013 | Karthik Radhakrishnan | Chief Financial Officer | Buy | $75K (50,000 @ $1.50) |
| Jun 14, 2010 | Neil K Warma | President & CEO | Buy | $8K (5,000 @ $1.62) |
| Jun 11, 2010 | David Emerson Jorden | Director | Buy | $46K (28,091 @ $1.62) |
| Jun 11, 2010 | Neil K Warma | President & CEO | Buy | $5K (3,000 @ $1.64) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.